InvestorWire NewsRoom

Article

Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)
January 6, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)

  • The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022
  • Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027
  • The advertising and media contract will allow SRAX to engage and manage social media companies for the creation and distribution of advertising materials promoting Lexaria Bioscience

Lexaria Bioscience (NASDAQ: LEXX), an innovator of drug delivery platforms, announced that it will kick off 2022 with an advertising and media agreement with SRAX (NASDAQ: SRAX) for media buys and digital marketing. The announcement is the first in a long line of plans that the company has made for the new year, a year anticipated to be the busiest yet for the company. The strategic move to bring on SRAX will help Lexaria increase its visibility to the investor community, enhancing the company’s exposure across all networks (https://ibn.fm/nBGuM).

Lexaria’s advertising and media contract with SRAX allows the latter to engage and manage media companies to create and distribute advertising materials made available online. SRAX will control when these communications are released to the online customer audience. As a financial technology company, SRAX uses cutting-edge algorithms to aid in maximizing engagement.

Chris Bunka, CEO of Lexaria, commented on the advertising and media contract, saying that his company was pleased to be working with SRAX to inform and engage a broad investor community in a year-long media outreach campaign. “Lexaria has made tremendous progress during 2021, and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors,” Bunka added.

The new year promises to be a busy one for the company, with several projects set to be initiated or conducted over the next 12 months:

  • a six-week human clinical trial to study hypertension and evaluate Lexaria’s DehydraTECH-CBD for the potential hypertension relief
  • a potentially industry-changing oral nicotine human study which will include both subjective evaluation and objective blood measurements to demonstrate the superiority of DehydraTECH-nicotine in comparison to leading industry products
  • animal studies designed to evaluate DehydraTECH-CBD for seizure relief and a comparison against the only FDA-approved pharmaceutical in use for treatment against certain seizure disorders
  • the company expects to complete its pre-IND meeting with the FDA during the new year and proceed with the IND application process, registering the clinical trial testing of DehydraTECH-CBD for hypertension

Lexaria’s patented DehydraTECH technology is designed to deliver fat-soluble drugs and other active pharmaceutical ingredients, increasing effectiveness and improving absorption into the bloodstream. By changing the way these pharmaceuticals are absorbed, Lexaria is speeding up the delivery and subsequent effects of the drug, increasing brain absorption, reducing drug administration costs, improving the potency of the drug, and even masking unwanted tastes.

The company is positioned to leverage its technology to gain access and cement its position in several markets worth billions in forecasted market value. For example, in 2020, the cannabidiol (CBD) market size surpassed $7.1 billion and is estimated to grow at a CAGR of 35%, topping $108.8 billion by 2027. Listed drivers for growth include an increase in medical applications for CBD (much like Lexaria’s DehydraTECH technology), increased product adaptations, increased retail sales, and more (https://ibn.fm/Am3bk).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).